TransMedics was founded to address the growing need for healthier organs for transplantation.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
TransMedics Group news
04.05.2022
TransMedics Group's GAAP loss for the 3 months of 2022 was $10.562 million, up 33.4% from $7.917 million in the previous year. Revenue increased 2.3 times to $15.88 million from $7.053 million a year earlier.
Source: investors.transmedics.com
24.02.2022
TransMedics Group's GAAP loss for 2021 was $44.215 million, up 53.8% from $28.748 million in the prior year. Revenue increased 18% to $30.262 million from $25.639 million a year earlier.
Source: investors.transmedics.com
10.11.2021
TransMedics Group's GAAP loss for 9M 2021 was $31.547 million, up 40.6% from $22.437 million in the prior year. Revenue increased 69.9% to $30.594 million from $18.012 million a year earlier.
Source: investors.transmedics.com
29.09.2021
TransMedics has received FDA premarket approval for the OCS Liver System. It is designed to maintain and monitor hemodynamic and metabolic function of the donor liver after donor brain death.
Source: investors.transmedics.com
General information
| Company name | TransMedics Group |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 200 MINUTEMAN ROAD ANDOVER MA 01810 9785520900 |
| Mailing address | 200 MINUTEMAN ROAD ANDOVER MA 01810 |
| Website | www.transmedics.com |
| Information disclosure | www.sec.gov |
English (US) 